isoniazid and rifapentine

Phase 3Small molecule

CCenters for Disease Control and Prevention

isoniazid and rifapentine is one of 68 small molecule programs targeting Diabetes Mellitus. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diabetes MellitusActive, not recruiting

TuberculosisActive, not recruiting

Diabetes MellitusPhase 3

Active, not recruiting

TuberculosisPhase 3

Active, not recruiting

Competition

Competitive Landscape

297 competitors in Tuberculosis

#DrugCompanyPhaseTrials

Rifadin

Sanofi

Phase 3

16 2

Avelox

Bayer

Phase 3

11 3

Lamprene

Novartis

Phase 3

5 4

Sirturo

WWim Janssens

Phase 3

10 5

Bayer Aspirin

Bayer

Phase 3

—6

TB Alliance

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

3 7

Deltavit

HHyundai Pharmaceutical Co., LTD.

Phase 3

2 8

BCG Vaccine

GGynecologic Oncology Group

Phase 3

1 9

Selenium

SSWOG Cancer Research Network

Phase 3

—10

Bacillus Calmette-Guerin

AstraZeneca

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 3Recruiting

Systemic

NCT06022146

Clinical

Trials by Indication[1]

Tuberculosis1 trial

Study 33: Adherence to Latent Tuberculosis Infection Treatment 3HP SAT Versus 3HP DOT

Completed·CCenters for Disease Control and Prevention·Phase 3·NCT01582711·1,002 enrolled

Systemic1 trial

TB YOUTH - TB sYstemic Management Using One-month, Ultra-short TPT Regimen for scHool Contacts

Recruiting·HHuashan Hospital·Phase 3·NCT06022146·3,520 enrolled

TBI1 trial

Risk of SDRs Under 3HP and 1HP Regimen for LTBI

Completed·NNational Taiwan University Hospital·Phase 3·NCT04094012·490 enrolled

Diabetes Mellitus1 trial

Preventive Treatment Of Latent Tuberculosis Infection In People With Diabetes Mellitus

Unknown status·—·Phase 3·NCT04600167·3,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for isoniazid and rifapentine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — isoniazid and rifapentine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for isoniazid and rifapentine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Centers for Disease Control and Prevention company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CCenters for Disease Control and Prevention

isoniazid and rifapentine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Tuberculosis1 trial

Systemic1 trial

TBI1 trial

Diabetes Mellitus1 trial

References

Drug Info

Quick Facts

Related News